 castrat nilutamid vs castrat placebo advanc prostat cancer review combin antiandrogen treatment surgic medic castrat efficaci endocrin treatment prostat cancer effect adren androgen nonsteroid antiandrogen promis result preliminari open studi short-term day comparison nilutamid buserelin buserelin placebo mg/day bone pain patient pain control group initi buserelin-induc increas prostat acid phosphatas nilutamid similar increas testosteron gonadotropin concentr control group tumor flare-up start hormone-releas hormon lh-rh treatment endocrin respons multicent double-blind placebo-control trial castrat patient combin nilutamid castrat bone pain perform statu number patient object regress patient nilutamid visual disord gastrointestin disord alcohol intoler patient result nilutamid efficaci castrat patient prostat cancer current studi effect treatment surviv risk-benefit ratio